Anser® UST

Simultaneously measures ustekinumab (UST) and antibodies to ustekinumab (UST) levels in serum at any time during therapy.

Multiple Advantages

  • Quantify whether inflammatory bowel disease patients have antibodies and/or sufficient drug concentrations
  • Measure antibodies in the presence of drugs (i.e., drug tolerant assay)
  • Overcome many of the limitations of solid-phase assays
  • Assay-specific drug and antibody levels correlated with clinical outcomes

For detailed information visit www.monitrcd.com/gh/ »

Sample insurance correspondence for PROMETHEUS® Anser® UST

Anser® VDZ

Simultaneously measures vedolizumab (VDZ) and antibodies to vedolizumab (ATV) levels in serum at any time during therapy.

Multiple Advantages

  • Quantify whether inflammatory bowel disease patients have antibodies and/or sufficient drug concentrations
  • Measure antibodies in the presence of drugs (i.e., drug tolerant assay)
  • Overcome many of the limitations of solid-phase assays
  • Assay-specific drug and antibody levels correlated with clinical outcomes

For detailed information visit www.monitrcd.com/gh/ »

The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® VZD

Anser® ADA

Simultaneously measures adalimumab (ADA) and antibodies to adalimumab (ATA) levels in serum at any time during therapy.

Multiple Advantages

  • Quantify whether inflammatory bowel disease patients have antibodies and/or sufficient drug concentrations
  • Measure antibodies in the presence of drugs (i.e., drug tolerant assay)
  • Overcome many of the limitations of solid-phase assays
  • Assay-specific drug and antibody levels correlated with clinical outcomes

For detailed information visit www.monitrcd.com/gh/ »

The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® ADA

Anser® IFX

Simultaneously measures infliximab (IFX) and antibodies to infliximab (ATI) levels in serum at any time during therapy. Can also be used with IFX biosimilars.

Multiple Advantages

  • Quantify whether inflammatory bowel disease patients have antibodies and/or sufficient drug concentrations
  • Measure antibodies in the presence of drugs (i.e., drug tolerant assay)
  • Overcome many of the limitations of solid-phase assays
  • Assay-specific drug and antibody levels correlated with clinical outcomes

For detailed information visit www.monitorcd.com/gh »


The Prometheus Anser® tests are quantitative monitoring assays that allow healthcare providers to measure and monitor both the levels of drug and anti-drug antibodies at anytime during therapy. Incorporating drug monitoring may clarify what factors are contributing to a patient’s loss of response and help guide treatment decisions by providing information to help determine an appropriate course of action.

Sample insurance correspondence for PROMETHEUS® Anser® IFX